2025-07-21
Important Notice to Long-Term Shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR); Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, July 21, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR):Grabar Law Office is investigating claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ:CAPR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Capricor (NASDAQ:CAPR) shares prior to October 9, 2024 and still hold shares today, please visit https://grabarlaw.com/the-latest/capricor-shareholder-investigation/, contact Joshua Grabar at [email protected], or call us at 267-507-6085 to learn more. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If, alternatively, you purchased your shares between October 9, 2024, and July 10, 2025, you can participate in the class action.WHY? As alleged in a recently filed federal securities fraud class action, Capricor and its Chief Executive Officer, provided investors with overwhelmingly positive statements to investors as to material information concerning Capricor's lead cell therapy candidate drug deramiocel – used for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. These statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration.The Complaint alleges that these overwhelmingly positive statements were made to investors while, at the same time, Capricor and its CEO disseminated false and misleading statements and/or concealed material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel, causing Plaintiff and other shareholders to purchase Capricor's securities at artificially inflated pricesWHAT YOU CAN DO NOW: If you purchased Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares prior to October 9, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/capricor-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If, alternatively, you purchased your shares between October 9, 2024, and July 10, 2025, you can participate in the class action. #Capricor $CAPRCentene Corporation (NYSE:CNC):Grabar Law Office is investigating claims on behalf of shareholders of Centene Corporation (NYSE:CNC). The investigation concerns whether certain officers and directors breached the fiduciary duties they ...Full story available on Benzinga.com
